Response to Correspondence: Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy? Jorgensen et al.

Titanji, Boghuma K; Farley, Monica M; Schinazi, Raymond F; Marconi, Vincent C

Titanji, Boghuma K; Farley, Monica M; Schinazi, Raymond F; Marconi, Vincent C.

Titanji BK; Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA.
Farley MM; Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA.
Schinazi RF; Infectious Diseases, Atlanta Veterans Affairs Medical Center, Decatur, Georgia, USA.
Marconi VC; Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.

Clin Infect Dis ; 73(11): e3980-e3981, 2021 12 06.

Article in English | MEDLINE | ID: covidwho-1612451

Subject(s)

Azetidines; COVID-19 Drug Treatment; Humans; Purines; Pyrazoles; SARS-CoV-2; Sulfonamides

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Azetidines / COVID-19 Drug Treatment Type of study: Experimental Studies Limits: Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: Cid

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google